Accelerator mass spectrometry in biomedical dosimetry: relationship between low-level exposure and covalent binding of heterocyclic amine carcinogens to DNA - Wikidata - awgldk - TriplyDB

Accelerator mass spectrometry in biomedical dosimetry: relationship between low-level exposure and covalent binding of heterocyclic amine carcinogens to DNA

Accelerator mass spectrometry in biomedical dosimetry: relationship between low-level exposure and covalent binding of heterocyclic amine carcinogens to DNA

http://www.wikidata.org/entity/Q33682836

about

Integrated approach for evaluating species and interindividual differences in responsiveness to dioxins and structural analogs Low-level biological dosimetry of heterocyclic amine carcinogens isolated from cooked food Metabolism and biomarkers of heterocyclic aromatic amines in molecular epidemiology studies: lessons learned from aromatic amines Analytical validation of accelerator mass spectrometry for pharmaceutical development Opportunities in low-level radiocarbon microtracing: applications and new technology DNA adducts of heterocyclic amine food mutagens: implications for mutagenesis and carcinogenesis.Calculating radiation exposures during use of (14)C-labeled nutrients, food components, and biopharmaceuticals to quantify metabolic behavior in humans Accelerator mass spectrometry-enabled studies: current status and future prospects.Animal studies addressing the carcinogenicity of TCDD (or related compounds) with an emphasis on tumour promotion.Salvage of oxidized guanine derivatives in the (2'-deoxy)ribonucleotide pool as source of mutations in DNA.Use of microdosing and accelerator mass spectrometry to evaluate the pharmacokinetic linearity of a novel tricyclic GyrB/ParE inhibitor in rats Quantifying exploratory low dose compounds in humans with AMS.Heterocyclic aromatic amine metabolism, DNA adduct formation, mutagenesis, and carcinogenesis.Molecular epidemiology in cancer risk assessment and prevention: recent progress and avenues for future research.Carbon isotopes profiles of human whole blood, plasma, red blood cells, urine and feces for biological/biomedical 14C-accelerator mass spectrometry applications Exposure to heterocyclic amines.Isotope-labeled immunoassays without radiation waste Big physics, small doses: the use of AMS and PET in human microdosing of development drugs.A microdosing approach for characterizing formation and repair of carboplatin-DNA monoadducts and chemoresistance.Breast cancer chemoprevention: risk-benefit effects of the antioestrogen tamoxifen.Attomole level protein sequencing by Edman degradation coupled with accelerator mass spectrometry.Determining the pharmacokinetics and long-term biodistribution of SiO2 nanoparticles in vivo using accelerator mass spectrometry.Cytochrome P450-mediated metabolism and DNA binding of 2-amino-1,7-dimethylimidazo[4,5-g]quinoxaline and its carcinogenic isomer 2-amino-3,8-dimethylimidazo[4,5-f]quinoxaline in mice.Disposition of the Dietary Mutagen 2-Amino-3,8-dimethylimidazo[4,5-f]quinoxaline in Healthy and Pancreatic Cancer Compromised Humans.Stability and reactivity of 2-nitrosoamino-3,8-dimethylimidazo[4,5-f]quinoxaline.Novel LC-ESI/MS/MS(n) method for the characterization and quantification of 2'-deoxyguanosine adducts of the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine by 2-D linear quadrupole ion trap mass spectrometry Recent advances in biomedical applications of accelerator mass spectrometry.Investigating the biochemical impact of DNA damage with structure-based probes: abasic sites, photodimers, alkylation adducts, and oxidative lesions.Furan carcinogenicity: DNA binding and genotoxicity of furan in rats in vivo.Quantifying Carbon-14 for Biology Using Cavity Ring-Down Spectroscopy.Microdosing and Other Phase 0 Clinical Trials: Facilitating Translation in Drug Development.Challenging developments in three decades of accelerator mass spectrometry at ETH: from large particle accelerators to table size instruments.Bioanalytical aspects of clinical mass balance studies in oncology.Accelerator MS: its role as a frontline bioanalytical technique.Biological and biomedical (14)C-accelerator mass spectrometry and graphitization of carbonaceous samples.Mode of action and dose-response framework analysis for receptor-mediated toxicity: The aryl hydrocarbon receptor as a case study.Approaches to intravenous clinical pharmacokinetics: Recent developments with isotopic microtracers.Phase-0/microdosing studies using PET, AMS, and LC-MS/MS: a range of study methodologies and conduct considerations. Accelerating development of novel pharmaceuticals through safe testing in humans - a practical guide.Use of accelerator mass spectrometry for studies in nutrition.Transgenic animal models for measuring mutations in vivo.

P2860

Q28327185-9A180F1B-AEE4-44F2-828D-6845E029EC39 Q28390651-53258099-A4EA-43B5-A400-66D8D8885AF3 Q28391158-579CED0A-5BA3-4D61-8A19-EB9A6634BC90 Q28743669-8B5BA705-8D6B-49EF-8098-CE92A6774127 Q28817904-609B4550-F8BD-43B4-9B6A-DCD867D3FBCC Q33586628-CA7AB3ED-E5FA-4629-8C5E-539DA25A3C87 Q33803400-A019FD5D-1499-41F7-A997-D4F5351BA667 Q33819361-0A52EF1A-7E30-4848-80D2-131F159BD757 Q33911322-F5A428B9-5F5E-47A8-A727-FA0417B40BD2 Q34348727-EE51A899-D921-4238-90F6-5711E791F52B Q34596727-DF5CF7AD-9554-429E-A29C-0C6CB716A405 Q34708648-E9C8E167-6C5E-4BFF-BF8C-15A4F6D20283 Q34819148-05335160-42C3-47ED-9E3A-F3E5A08B098E Q34844361-392E2310-A236-4946-88E6-26EAA91C0586 Q34918079-907F6D13-9911-4994-83E2-AE37B48B0623 Q35031449-EF86506D-DFDC-43B8-A8B9-5C61455F44C3 Q35073607-D405E8D3-DBCF-43A8-BD72-0B2E18A245FB Q35075780-0DDB8742-6AE6-46E8-B0A0-8CEBE3C36475 Q35131936-84ACBA3D-08BF-43D1-8651-B0EFE566115B Q35194482-AEFC834E-ABB6-4A0E-B788-D4050E48B729 Q35252821-A2C66149-566B-43C2-8368-EC607B928529 Q36402145-5090A047-C81D-447F-B4B1-97731C315C26 Q36493140-A206D180-2246-49AC-8B84-6D0D0848EEE8 Q36798273-F1C74E2E-D0A6-42E9-9F35-A317B70ECCCF Q36882341-E9922411-E700-4B89-B8F4-399EFBBDCA8E Q36995526-945AB729-CDCF-447E-9FC6-7E8DDC07731F Q37266360-D5AC04CF-BDCE-4737-9AE5-A841D99B6068 Q37462441-C0D6FC54-A449-46EA-AD2C-925A31084492 Q37480300-0CAAEA3D-21B5-46FC-8DB8-5D14C77778F4 Q37600860-494E8199-E3AF-4E04-8999-948324FBD007 Q37701128-1B08A078-4998-4EF1-8508-1570CB8E81CF Q37763426-1F8464E7-F208-4B58-95BD-13C8472EFDC5 Q37963912-682B5C83-BC7D-4934-BABE-77FA6B98FD73 Q37970117-27EDDE1D-BAF0-4053-ADF1-E4C0036C83CE Q38102700-C2C779F8-897C-45D9-9AD7-3955475792A9 Q38163594-49EECDF1-0698-485B-B529-D030575A2BE7 Q38527478-627CC85F-AD93-47FE-A81D-D79D8E85458F Q38937832-0C7EB4C7-F0B9-4D6F-8DBF-1C31EAC6EABF Q40674194-9F46D451-5FC1-44E2-B52E-4C6B213A0255 Q41053143-447D9EB2-D999-4CBF-AEDC-4C25E6327FA9

P2860

Accelerator mass spectrometry in biomedical dosimetry: relationship between low-level exposure and covalent binding of heterocyclic amine carcinogens to DNA

http://www.wikidata.org/entity/Q33682836

description

1990 nî lūn-bûn

@nan

1990 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

1990 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

1990年の論文

@ja

1990年論文

@yue

1990年論文

@zh-hant

1990年論文

@zh-hk

1990年論文

@zh-mo

1990年論文

@zh-tw

1990年论文

@wuu

name

Accelerator mass spectrometry ...... yclic amine carcinogens to DNA

@ast

Accelerator mass spectrometry ...... yclic amine carcinogens to DNA

@en

type

label

Accelerator mass spectrometry ...... yclic amine carcinogens to DNA

@ast

Accelerator mass spectrometry ...... yclic amine carcinogens to DNA

@en

prefLabel

Accelerator mass spectrometry ...... yclic amine carcinogens to DNA

@ast

Accelerator mass spectrometry ...... yclic amine carcinogens to DNA

@en

P1433

Q33682836-43C87F3E-C7C0-44BC-B71D-FC4C8472B16A

P1476

Q33682836-8E3D974D-D82E-4617-AE20-2A9490CE3533

P2093

Q33682836-395CC887-9C02-406F-9C14-CD96D13A9425

Q33682836-7FFFA74E-8637-43B7-BF0A-DC325FEB655A

Q33682836-8414FDF6-6D11-4546-8B2D-5A975B3DE470

Q33682836-94A94746-BDE3-4FF2-82FF-FCCDA9C52894

Q33682836-A72A3E8A-3E9C-4532-B8E9-FA635C1969C5

Q33682836-C18D66C8-B18C-4371-8196-08982886B847

Q33682836-CDDCC1EC-86A1-4D5B-8E1A-BE5BBC20FB95

Q33682836-E6EA1CAA-D64D-4ED1-84F6-5D168C666408

Q33682836-EB38EFAC-D601-41B8-9CD5-D6F97B3E584F

Q33682836-F59FBBE9-83BB-4080-ACC5-06EBCA44DCDE

P2860

Q33682836-08C71412-6E05-45BA-9997-0BE02D27F73B

Q33682836-092E6977-F089-476D-88C0-5F4F467189FC

Q33682836-0983B846-6DC4-4767-9D6F-EF1F6A074DC2

Q33682836-0E6D0A04-9B2C-4403-829A-332C8FE37772

Q33682836-1CC84D8E-0B61-444E-AAB7-8E31DE14AA47

Q33682836-2B1BD986-02A7-4788-BFB0-E09C51C3447A

Q33682836-33A265EC-8DB7-4390-8758-25333D3365F5

Q33682836-56E2061A-687F-4A3C-BA1E-30D3BADF7C1B

Q33682836-61C21AB2-ECF2-46A0-8D5D-81B890222147

Q33682836-74FC5AD2-74BD-42B2-9FB4-0CA228358B2F

P304

Q33682836-DC3A79F1-402F-4C3B-85AA-D584272EE821

P31

Q33682836-494179C7-8A3D-42D4-A76F-F6D667B30AF1

P356

Q33682836-F20B7EF6-B95F-4D30-87B2-0895F3887D69

P407

Q33682836-CA56B8C2-FDFF-444D-8D4D-9A139D6B34C0

P433

Q33682836-2A110439-C18B-4A80-9C24-7342F5CA5B12

P478

Q33682836-ABB6F834-58D5-4C97-8CD1-C54775A45F87

P577

Q33682836-8B8674D8-E25C-4CFE-8BAB-E63DAB374CA9

P5875

Q33682836-BE33A4C3-A702-422A-BDB3-62E4D92FA10E

P698

Q33682836-67A19FA2-E623-4330-8408-035234B26320

P932

Q33682836-1A728247-EA1D-4659-B376-9F3A6D430310

P356

PNAS.87.14.5288

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Accelerator mass spectrometry ...... yclic amine carcinogens to DNA

@en

P2093

B L Gledhill

http://www.w3.org/2001/XMLSchema#string

D E Nelson

http://www.w3.org/2001/XMLSchema#string

I D Proctor

http://www.w3.org/2001/XMLSchema#string

J C Davis

http://www.w3.org/2001/XMLSchema#string

J R Southon

http://www.w3.org/2001/XMLSchema#string

J S Felton

http://www.w3.org/2001/XMLSchema#string

J S Vogel

http://www.w3.org/2001/XMLSchema#string

K W Turteltaub

http://www.w3.org/2001/XMLSchema#string

M W Caffee

http://www.w3.org/2001/XMLSchema#string

R C Finkel

http://www.w3.org/2001/XMLSchema#string

P2860

Detection of benzo[a]pyrene diol epoxide-DNA adducts in peripheral blood lymphocytes and antibodies to the adducts in serum from coke oven workers

Identification of the mutagens in cooked beef.

Benzo(a)pyrene diolepoxide-DNA adducts detected by synchronous fluorescence spectrophotometry

Laser-induced room-temperature phosphorescence detection of benzo[a]pyrene-DNA adducts.

Nonrandom binding of the carcinogen N-hydroxy-2-acetylaminofluorene to repetitive sequences of rat liver DNA in vivo.

Role of metabolism on the DNA binding of MeIQx in mice and bacteria.

32P-adduct assay: comparative recoveries of structurally diverse DNA adducts in the various enhancement procedures.

A convenient synthesis of the potent mutagen 3,4,8-trimethyl-3H-imidazo[4,5-f]quinoxalin-2-amine.

Accelerator mass spectrometry for measurement of long-lived radioisotopes.

Metabolism of the food-borne mutagen/carcinogen 2-amino-3,8-dimethylimidazo[4,5-f]quinoxaline in the rat: assessment of biliary metabolites for genotoxicity.

P304

5288-5292

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.87.14.5288

http://www.w3.org/2001/XMLSchema#string

P407

P433

14

http://www.w3.org/2001/XMLSchema#string

P478

87

http://www.w3.org/2001/XMLSchema#string

P577

1990-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

20785362

http://www.w3.org/2001/XMLSchema#string

P698

2371271

http://www.w3.org/2001/XMLSchema#string

P932

54308

http://www.w3.org/2001/XMLSchema#string